Ipamorelin is a growth hormone secretagogue (GHS) peptide that stimulates the release of growth hormone from the anterior pituitary gland. It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Ipamorelin was derived from GHRP-1, another GHS peptide.
Ipamorelin is different from other GHS peptides in a few ways. First, it is more selective for the growth hormone-releasing hormone (GHRH) receptor, which means that it is less likely to cause other side effects, such as increased cortisol levels. Second, ipamorelin has a longer half-life, which means that it can be administered less frequently.
Ipamorelin is currently being investigated for the treatment of a variety of conditions, including:
- Growth hormone deficiency: Ipamorelin has been shown to increase growth hormone levels and promote growth in children with growth hormone deficiency.
- Muscle wasting: Ipamorelin has been shown to increase muscle mass and strength in people with muscle wasting, such as those with HIV/AIDS or cancer.
- Osteoporosis: Ipamorelin is being investigated for its potential to improve bone density and reduce the risk of fractures in people with osteoporosis.
- Diabetes: Ipamorelin is being investigated for its potential to improve glucose control in people with type 2 diabetes.
- Heart disease: Ipamorelin is being investigated for its potential to improve heart function and reduce the risk of heart failure in people with heart disease.
- Stroke: Ipamorelin is being investigated for its potential to improve cognitive function and reduce the risk of disability in people who have had a stroke.
- Alzheimer’s disease: Ipamorelin is being investigated for its potential to slow the progression of Alzheimer’s disease and improve cognitive function in people with the disease.
Ipamorelin is not yet approved by the US Food and Drug Administration (FDA) for any use. It is considered an investigational drug and is only available through clinical trials.
In addition to the potential uses listed above, ipamorelin is also being investigated as a potential performance enhancer for athletes. However, more research is needed to determine the safety and efficacy of ipamorelin for this use.
How to use ipamorelin
Ipamorelin is typically administered by injection. It can be injected subcutaneously (under the skin) or intramuscularly (into the muscle). Ipamorelin is typically injected three times per day, but the exact dosage and schedule will vary depending on the individual’s condition.
Potential side effects of ipamorelin
Ipamorelin is generally well-tolerated, but it can cause some side effects, such as:
- Headache
- Nausea
- Vomiting
- Muscle cramps
- Joint pain
- Fluid retention
Ipamorelin should not be used by people who have cancer, are pregnant or breastfeeding, or have diabetes. It should also not be used by people who are taking certain medications, such as insulin or corticosteroids.
Ipamorelin is a promising new therapy for a variety of conditions. It is important to note that ipamorelin is an investigational drug and is not yet approved by the US Food and Drug Administration (FDA) for any use. More research is needed to determine the long-term safety and efficacy of ipamorelin therapy.
If you are interested in learning more about ipamorelin, talk to your doctor.
